789 related articles for article (PubMed ID: 10215595)
1. Resistance of small leucine-rich repeat proteoglycans to proteolytic degradation during interleukin-1-stimulated cartilage catabolism.
Sztrolovics R; White RJ; Poole AR; Mort JS; Roughley PJ
Biochem J; 1999 May; 339 ( Pt 3)(Pt 3):571-7. PubMed ID: 10215595
[TBL] [Abstract][Full Text] [Related]
2. Degradation of small leucine-rich repeat proteoglycans by matrix metalloprotease-13: identification of a new biglycan cleavage site.
Monfort J; Tardif G; Reboul P; Mineau F; Roughley P; Pelletier JP; Martel-Pelletier J
Arthritis Res Ther; 2006; 8(1):R26. PubMed ID: 16507124
[TBL] [Abstract][Full Text] [Related]
3. Proteoglycans and diseases of soft tissues.
Halper J
Adv Exp Med Biol; 2014; 802():49-58. PubMed ID: 24443020
[TBL] [Abstract][Full Text] [Related]
4. Aggrecanase versus matrix metalloproteinases in the catabolism of the interglobular domain of aggrecan in vitro.
Little CB; Flannery CR; Hughes CE; Mort JS; Roughley PJ; Dent C; Caterson B
Biochem J; 1999 Nov; 344 Pt 1(Pt 1):61-8. PubMed ID: 10548534
[TBL] [Abstract][Full Text] [Related]
5. The mechanism of aggrecan release from cartilage differs with tissue origin and the agent used to stimulate catabolism.
Sztrolovics R; White RJ; Roughley PJ; Mort JS
Biochem J; 2002 Mar; 362(Pt 2):465-72. PubMed ID: 11853556
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal antibodies that specifically recognize neoepitope sequences generated by 'aggrecanase' and matrix metalloproteinase cleavage of aggrecan: application to catabolism in situ and in vitro.
Hughes CE; Caterson B; Fosang AJ; Roughley PJ; Mort JS
Biochem J; 1995 Feb; 305 ( Pt 3)(Pt 3):799-804. PubMed ID: 7531436
[TBL] [Abstract][Full Text] [Related]
7. Fragmentation of decorin, biglycan, lumican and keratocan is elevated in degenerate human meniscus, knee and hip articular cartilages compared with age-matched macroscopically normal and control tissues.
Melrose J; Fuller ES; Roughley PJ; Smith MM; Kerr B; Hughes CE; Caterson B; Little CB
Arthritis Res Ther; 2008; 10(4):R79. PubMed ID: 18620607
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the degradation of type II collagen and proteoglycan in nasal and articular cartilages induced by interleukin-1 and the selective inhibition of type II collagen cleavage by collagenase.
Billinghurst RC; Wu W; Ionescu M; Reiner A; Dahlberg L; Chen J; van Wart H; Poole AR
Arthritis Rheum; 2000 Mar; 43(3):664-72. PubMed ID: 10728761
[TBL] [Abstract][Full Text] [Related]
9. Cytokine-induced cartilage proteoglycan degradation is mediated by aggrecanase.
Arner EC; Hughes CE; Decicco CP; Caterson B; Tortorella MD
Osteoarthritis Cartilage; 1998 May; 6(3):214-28. PubMed ID: 9682788
[TBL] [Abstract][Full Text] [Related]
10. Fibromodulin and lumican bind to the same region on collagen type I fibrils.
Svensson L; Närlid I; Oldberg A
FEBS Lett; 2000 Mar; 470(2):178-82. PubMed ID: 10734230
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of cartilage degradation and changes in physical properties induced by IL-1beta and retinoic acid using matrix metalloproteinase inhibitors.
Bonassar LJ; Sandy JD; Lark MW; Plaas AH; Frank EH; Grodzinsky AJ
Arch Biochem Biophys; 1997 Aug; 344(2):404-12. PubMed ID: 9264555
[TBL] [Abstract][Full Text] [Related]
12. Highly sulfated glycosaminoglycans inhibit aggrecanase degradation of aggrecan by bovine articular cartilage explant cultures.
Munteanu SE; Ilic MZ; Handley CJ
Matrix Biol; 2002 Aug; 21(5):429-40. PubMed ID: 12225808
[TBL] [Abstract][Full Text] [Related]
13. SLRP interaction can protect collagen fibrils from cleavage by collagenases.
Geng Y; McQuillan D; Roughley PJ
Matrix Biol; 2006 Oct; 25(8):484-91. PubMed ID: 16979885
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of bovine nasal cartilage degradation by selective matrix metalloproteinase inhibitors.
Bottomley KM; Borkakoti N; Bradshaw D; Brown PA; Broadhurst MJ; Budd JM; Elliott L; Eyers P; Hallam TJ; Handa BK; Hill CH; James M; Lahm HW; Lawton G; Merritt JE; Nixon JS; Röthlisberger U; Whittle A; Johnson WH
Biochem J; 1997 Apr; 323 ( Pt 2)(Pt 2):483-8. PubMed ID: 9163342
[TBL] [Abstract][Full Text] [Related]
15. Changes in leucine-rich repeat proteoglycans during maturation of the bovine growth plate.
Alini M; Roughley PJ
Matrix Biol; 2001 Jan; 19(8):805-13. PubMed ID: 11223340
[TBL] [Abstract][Full Text] [Related]
16. Cartilage degradation independent of MMP/aggrecanases.
Sugimoto K; Iizawa T; Harada H; Yamada K; Katsumata M; Takahashi M
Osteoarthritis Cartilage; 2004 Dec; 12(12):1006-14. PubMed ID: 15564068
[TBL] [Abstract][Full Text] [Related]
17. The cleavage of biglycan by aggrecanases.
Melching LI; Fisher WD; Lee ER; Mort JS; Roughley PJ
Osteoarthritis Cartilage; 2006 Nov; 14(11):1147-54. PubMed ID: 16806997
[TBL] [Abstract][Full Text] [Related]
18. Lumican inhibits collagen deposition in tissue engineered cartilage.
Kafienah W; Cheung FL; Sims T; Martin I; Miot S; Von Ruhland C; Roughley PJ; Hollander AP
Matrix Biol; 2008 Jul; 27(6):526-34. PubMed ID: 18534835
[TBL] [Abstract][Full Text] [Related]
19. Proteodermatan and proteokeratan sulfate (decorin, lumican/fibromodulin) proteins are horseshoe shaped. Implications for their interactions with collagen.
Scott JE
Biochemistry; 1996 Jul; 35(27):8795-9. PubMed ID: 8688414
[TBL] [Abstract][Full Text] [Related]
20. Small proteoglycans in human diabetic nephropathy: discrepancy between glomerular expression and protein accumulation of decorin, biglycan, lumican, and fibromodulin.
Schaefer L; Raslik I; Grone HJ; Schonherr E; Macakova K; Ugorcakova J; Budny S; Schaefer RM; Kresse H
FASEB J; 2001 Mar; 15(3):559-61. PubMed ID: 11259366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
